New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - salmonella typhi vi polysaccharide 25ug (salmonella typhi vi polysaccharide (ty2 strain)); hepatitis a virus formaldehyde inactivated, gbm strain 160 u - solution for injection - active: salmonella typhi vi polysaccharide 25ug (salmonella typhi vi polysaccharide (ty2 strain)) excipient: dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water for injection active: hepatitis a virus formaldehyde inactivated, gbm strain 160 u excipient: aluminium hydroxide as aluminium formaldehyde medium 199 phenoxyethanol as 2-phenoxyethanol solution 2.5µl - vivaxim® is indicated for simultaneous active immunisation against typhoid fever and hepatitis a virus infections in subjects aged 16 and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - salmonella typhi vi polysaccharide 25ug - solution for injection - 25µg/0.5ml - active: salmonella typhi vi polysaccharide 25ug excipient: dibasic sodium phosphate hydrochloric acid monobasic sodium phosphate dihydrate phenol sodium chloride sodium hydroxide water for injection - typhim vi™ is indicated for active immunisation against typhoid fever caused by salmonella typhi in individuals 2 years of age and over.

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - salmonella typhi ty2 vi polysaccharide antigen (unii: 7194h8w3kt) (salmonella typhi ty2 vi polysaccharide antigen - unii:7194h8w3kt) - salmonella typhi ty2 vi polysaccharide antigen 25 ug in 0.5 ml - typhim vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by s typhi and is approved for use in persons two years of age or older. immunization with typhim vi vaccine should occur at least two weeks prior to expected exposure to s typhi . typhim vi vaccine is not indicated for routine immunization of individuals in the united states (us). (14) selective immunization against typhoid fever is recommended under the following circumstances: 1) travelers to areas where a recognized risk of exposure to typhoid exists, particularly ones who will have prolonged exposure to potentially contaminated food and water, 2) persons with intimate exposure (ie, continued household contact) to a documented typhoid carrier, and 3) workers in microbiology laboratories who frequently work with s typhi . (14) typhoid vaccination is not required for international travel, but is recommended for travelers to such areas as africa, asia, and central and south america where there is a recognized r

United States - English - NLM (National Library of Medicine)

a-s medication solutions - salmonella typhi ty2 vi polysaccharide antigen (unii: 7194h8w3kt) (salmonella typhi ty2 vi polysaccharide antigen - unii:7194h8w3kt) - salmonella typhi ty2 vi polysaccharide antigen 25 ug in 0.5 ml - typhim vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by s typhi and is approved for use in persons two years of age or older. immunization with typhim vi vaccine should occur at least two weeks prior to expected exposure to s typhi . typhim vi vaccine is not indicated for routine immunization of individuals in the united states (us). (14) selective immunization against typhoid fever is recommended under the following circumstances: 1) travelers to areas where a recognized risk of exposure to typhoid exists, particularly ones who will have prolonged exposure to potentially contaminated food and water, 2) persons with intimate exposure (ie, continued household contact) to a documented typhoid carrier, and 3) workers in microbiology laboratories who frequently work with s typhi . (14) typhoid vaccination is not required for international travel, but is recommended for travelers to such areas as africa, asia, and central and south america where there is a recognized r

United States - English - NLM (National Library of Medicine)

a-s medication solutions - salmonella typhi ty2 vi polysaccharide antigen (unii: 7194h8w3kt) (salmonella typhi ty2 vi polysaccharide antigen - unii:7194h8w3kt) - salmonella typhi ty2 vi polysaccharide antigen 25 ug in 0.5 ml - typhim vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by s typhi and is approved for use in persons two years of age or older. immunization with typhim vi vaccine should occur at least two weeks prior to expected exposure to s typhi . typhim vi vaccine is not indicated for routine immunization of individuals in the united states (us). (14) selective immunization against typhoid fever is recommended under the following circumstances: 1) travelers to areas where a recognized risk of exposure to typhoid exists, particularly ones who will have prolonged exposure to potentially contaminated food and water, 2) persons with intimate exposure (ie, continued household contact) to a documented typhoid carrier, and 3) workers in microbiology laboratories who frequently work with s typhi . (14) typhoid vaccination is not required for international travel, but is recommended for travelers to such areas as africa, asia, and central and south america where there is a recognized r

Malta - English - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - vi polysaccharide, of salmonella, typhi - solution for injection - vi polysaccharide of salmonella typhi 25 µg - vaccines

Malta - English - Medicines Authority

smithkline beecham limited 980, great west road, brentford middlesex tw8 9gs, united kingdom - vi polysaccharide, of salmonella, typhi - solution for injection - vi polysaccharide of salmonella typhi 1 µg - vaccines

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - salmonella typhi vi polysaccharide, quantity: 0.025 mg - injection, solution - excipient ingredients: monobasic sodium phosphate; phenol; water for injections; sodium chloride; dibasic sodium phosphate dihydrate - for the active immunisation against typhoid fever, in subjects over 5 years of age. indications as at 9 october 2000: typhim vi is indicated for active immunisation against typhoid fever in subjects 2 years of age and over.

Israel - English - Ministry of Health

sanofi israel ltd - purified vi capsular polysaccharide of s.typhi - solution for injection - purified vi capsular polysaccharide of s.typhi 0.025 mg / 0.5 ml - typhoid, purified polysaccharide antigen - typhoid, purified polysaccharide antigen - typhim vi vaccine is indicated for active immunization against typhoid fever for persons two years of age or older.

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - vi polysaccharide of salmonella typhi, hepatit a virus antigen - suspension for injection - bacterial and viral vaccines, combined